Influence of direct acting antivirals with/without ribavirin on hematological parameters in cirrhosis with HCV

Authors

Keywords:

thrombocytopenia, leukopenia, Anemia, cirrhosis, daclatasvir, ledipasvir, ribavirin

Abstract

Direct-acting antivirals (DAAs) have revolutionized the treatment of hepatitis C virus (HCV) infection, especially for patients with liver cirrhosis. The aim of this study was to evaluate the hematological effect of AAD with/without ribavirin in HCV cirrhosis. The study was realised on 144 patients with cirrhosis HCV: group I - Sofosbuvir and Daclatasvir/Ledipasvir with ribavirin (RBV), for 12 weeks, group II - Sofosbuvir and Daclatasvir/Ledipasvir for 24 weeks. At baseline, 31 (21.5%) patients had severe thrombocytopenia, 68 (47.2%) patients had moderate thrombocytopenia. At the end of antiviral therapy, 15 (10.4%) patients maintained severe thrombocytopenia (p<0.001). At the initiation of antiviral therapy, 45 (31.2%) patients had normal platelet values, and at the end of treatment, 60 (41.6%) patients had normal platelet values. Patients who started treatment with AAD in combination with RBV had hemoglobin levelhigher than 110g/l at the initiation of antiviral therapy, the reason being anemia as an effect of RBV administration. Thus, at the end of the antiviral therapy, 12 (16.6%) patients from the first group had Hb values ≤ 109g/l compared to the second group - 1 (1.3%) patient (p<0.001). RBV dose adjustment was required in 26 (36.11%) patients and RBV discontinuation in 10 (13.8%) patients. Sustained virologic response (SVR) was present in 136 (94.4%) patients. The eradication of HCV infection by obtaining SVR in patients with liver cirrhosis presents an effective strategy in improving the hematological parameters.

References

1. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. In: J Hepatol. 2018, 69, pp. 461-511. https://doi.org/10.1016/j.jhep.2018.03.026

2. Lingas E. Hematological Abnormalities in Cirrhosis: A Narrative Review. In: Cureus. 2023, nr. 15(5), e39239. https://doi.org/10.7759/cureus.39239

3. Amir A., Qamar N., Grace R., Guadalupe G. T., Bosch J., Andrew K. et al. Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis. In: Clin Gastroenterol Hepatol. 2009, nr. 6(7), pp. 689-695. https://doi.org/10.1016/j.cgh.2009.02.021

4. Manish M., Saurabh D., Kapoor R., Sharad S., Singh A. Anemia in cirrhosis: An underestimated entity. In: World J Clin Cases. 2022, nr 10(3), pp. 777-789. https://doi.org/10.12998/wjcc.v10.i3.777

5. Scheiner B., Semmler G., Maurer F., Schwabl P., Bucsics T., Paternostro R. et al. Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. In: Liver Int. 2020, nr. 40(1), pp. 194-204. https://doi.org/10.1111/liv.14229

6. Kanda T., Matsuoka S., Moryama M. Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt. In: Hepatology International. 2018, nr. 12(4), pp. 291-293. https://doi.org/10.1007/s12072-018-9883-9

7. Rawi S., Wu G. Y. Pathogenesis of Thrombocytopenia in Chronic HCV Infection: A Review. In: J Clin Transl Hepatol. 2020, nr. 8(2), pp.184-191. https://doi.org/10.14218/JCTH.2020.00007

8. Sheikh, M. Y., Raoufi R., Atla, P. R. Prevalence of cirrhosis in patients with thrombocytopenia who receive bone marrow biopsy. In: Saudi J Gastroenterol. 2012, nr. 18(4), pp. 257-262. https://doi.org/10.4103/1319-3767.98431

9. Chao T. C., Chen C. Y., Yang Y. H., Chen P. M., Chang F. Y., Lee S. D. Chronic hepatitis C virus infection associated with primary warm-type autoimmune hemolytic anemia. In: J. Clin. Gastroenterol. 2001, nr 33, pp. 232-233. https://doi.org/10.1097/00004836-200109000-00014

10. Marincu I., Bratosin F., Curescu M., Suciu O. Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania. In: Medicina. 2021, nr. 57(9), p. 986. https://doi.org/10.3390/medicina57090986

11. Mitchell O., Feldman D., Diakow M., Sigal S. The pathophysiology of thrombocytopenia in chronic liver disease. In: Hepat Med. 2016, nr. 8, pp. 39-50. https://doi.org/10.2147/HMER.S74612

12. Gomez-Camarero J., Linares P., Calvo S. Long-term evolution of thrombocytopenia in patients with chronic hepatitis C and advanced fibrosis after sustained virological response with direct antiviral agents. In: J Hepatol. 2018, nr. 68, S549. https://doi.org/10.1016/S0168-8278(18)31356-4

13. Seko Y., Moriguchi M., Takahashi A., Okishio S., Kataoka S. The Association between the Platelet Count and Liver Volume in Compensated Cirrhosis Patients after the Eradication of Hepatitis C virus by Direct-acting Antivirals. In: Internal Medicine. 2020, nr. 59 (15), pp. 1811-1817. https://doi.org/10.2169/internalmedicine.4442-20

14. Ioannou G. N., Feld J. J. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? In: Gastroenterology. 2019, 156(2), pp. 446-460. https://doi.org/10.1053/j.gastro.2018.10.033

15. Saif-Al-Islam M., Abdelaal U., Younis M., Algany H., Khalaf S. Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease. In: Gastroenterology Research and Practice. 2021, ID 8811203. https://doi.org/10.1155/2021/8811203

16. Huang C. F., Yeh M. L., Huang C. I. et al. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. In: Hepatol Int. 2018, nr. 12, pp. 544-551. https://doi.org/10.1007/s12072-018-9908-4

17. Jer-Wei W., Tai-Chung T. Make platelet count great again: Direct-acting antiviral agenttherapy in patients with chronic hepatitis C. In: Adv Dig Med. 2019, nr. 6, pp. 91-92. https://doi.org/10.1002/aid2.13149

18. Toyoda H., Tada T., Yasuda S., Mizuno K., Ito T., Kumada T. Dynamic evaluation of liver fibrosis to assess the risk of hepatocellular carcinoma in patients with chronic hepatitis C who achieved sustained virologic response. In: Clin Infect Dis. 2020, 70(6), pp. 1208-1214. https://doi.org/10.1093/cid/ciz359

19. Toyoda H., Tada T., Kumada T. et al. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. In: Gastroenterol Hepatol. 2015, nr. 30, pp. 1183-1189. https://doi.org/10.1111/jgh.12915

20. Aleman S., Rahbin N., Weiland O. et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. In: Clin Infect Dis. 2013, nr. 57, pp. 230-236. https://doi.org/10.1093/cid/cit234

21. AASLD-IDSA HCV Guidance. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. In: Clin Infect Dis. 2018, 67 (10), pp. 1477-1492. https://doi.org/10.1093/cid/ciy585

Downloads

Published

2026-04-15

Issue

No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

[1]
Avricenco, M. et al. 2026. Influence of direct acting antivirals with/without ribavirin on hematological parameters in cirrhosis with HCV. Public Health Economy and Management in Medicine. 3(96) (Apr. 2026), 19–28.

Most read articles by the same author(s)

Similar Articles

1-10 of 26

You may also start an advanced similarity search for this article.